ES2161953T3 - Utilizacion del monosialogangliosido gm1 o del n-dicloroacetil-liso-gm1 para prevenir o invertir la degeneracion neuronal inducida por un tratamiento de larga duracion con l-dopa en la terapia de la enfermedad de parkinson. - Google Patents
Utilizacion del monosialogangliosido gm1 o del n-dicloroacetil-liso-gm1 para prevenir o invertir la degeneracion neuronal inducida por un tratamiento de larga duracion con l-dopa en la terapia de la enfermedad de parkinson.Info
- Publication number
- ES2161953T3 ES2161953T3 ES96116051T ES96116051T ES2161953T3 ES 2161953 T3 ES2161953 T3 ES 2161953T3 ES 96116051 T ES96116051 T ES 96116051T ES 96116051 T ES96116051 T ES 96116051T ES 2161953 T3 ES2161953 T3 ES 2161953T3
- Authority
- ES
- Spain
- Prior art keywords
- liso
- dopa
- prevent
- long
- dicloroacetil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE AL USO DE GANGLIOSIDOS GM{SUB,1} O EL DERIVADO DEL MISMO, N-DICLORO-ACETIL-LISO-GM1 (LIGA 20) PARA PREVENIR O REVERTIR LA DEGENERACION NEURONAL INDUCIDA POR UN TRATAMIENTO DE LARGA DURACION CON L-DOPA EN LA TERAPIA DE LA ENFERMEDAD DE PARKINSON.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI920591A IT1254280B (it) | 1992-03-13 | 1992-03-13 | Composizioni farmaceutiche comprendenti monosialoganglioside gm1 o un suo derivato atte al trattamento della malattia di parkinson |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2161953T3 true ES2161953T3 (es) | 2001-12-16 |
Family
ID=11362423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES96116051T Expired - Lifetime ES2161953T3 (es) | 1992-03-13 | 1993-03-12 | Utilizacion del monosialogangliosido gm1 o del n-dicloroacetil-liso-gm1 para prevenir o invertir la degeneracion neuronal inducida por un tratamiento de larga duracion con l-dopa en la terapia de la enfermedad de parkinson. |
Country Status (8)
Country | Link |
---|---|
US (1) | US6620792B1 (es) |
EP (2) | EP0630250A1 (es) |
JP (1) | JP2872809B2 (es) |
AT (1) | ATE206053T1 (es) |
DE (1) | DE69330842T2 (es) |
ES (1) | ES2161953T3 (es) |
IT (1) | IT1254280B (es) |
WO (1) | WO1993017691A2 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1259176B (it) * | 1992-10-23 | 1996-03-11 | Fidia Spa | Composizioni farmaceutiche comprendenti monosialoganglioside gm1 (o suo derivato) e fattore neuronotrofico ciliare (cntf) atte al trattamento di patologie del sistema nervoso |
JP2005527467A (ja) * | 2001-08-29 | 2005-09-15 | ネオーズ テクノロジーズ, インコーポレイテッド | 新規な合成ガングリオシド誘導体およびその組成物 |
EP1358910A1 (de) * | 2002-05-02 | 2003-11-05 | B.R.A.H.M.S Aktiengesellschaft | Verfahren und Mittel zur Prävention, Hemmung und Therapie von Krebserkrankungen |
EP1367395A1 (de) | 2002-05-02 | 2003-12-03 | B.R.A.H.M.S Aktiengesellschaft | Diagnose von Neoplasmen mit Hilfe von anti-Gangliosid-Antikörpern |
US7943750B2 (en) * | 2007-06-18 | 2011-05-17 | Laboratoire Medidom S.A. | Process for obtaining pure monosialoganglioside GM1 for medical use |
CN101732331B (zh) * | 2008-11-20 | 2012-05-23 | 北京四环制药有限公司 | 一种单唾液酸四己糖神经节苷脂钠与谷氨酸的组合物 |
US9463186B2 (en) | 2013-04-15 | 2016-10-11 | Northwestern University | Treatment for dopaminergic disorders |
CN104490837A (zh) * | 2014-12-30 | 2015-04-08 | 哈尔滨医科大学科技开发总公司 | 单唾液酸四己糖神经节苷脂钠的口服制剂 |
RU2632710C2 (ru) * | 2016-03-31 | 2017-10-09 | Лонг Шенг Фарма Лимитед | Способ получения натрий моносиалового ганглиозида и нейропротекторное средство на его основе |
CN108815131B (zh) * | 2018-09-11 | 2021-01-01 | 四川奇格曼药业有限公司 | 一种神经节苷脂缓释片及其制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1199116B (it) | 1984-07-03 | 1988-12-30 | Fidia Farmaceutici | Derivati di gangliosidi |
IT1208751B (it) * | 1986-06-30 | 1989-07-10 | Fidia Farmaceutici | Possibile uso dei gangliosidi esogeni in malattie tumorali come fattore protettivo contro la neurotossicita' da farmaci antitumorali |
IT1235161B (it) * | 1988-12-02 | 1992-06-22 | Fidia Farmaceutici | Derivati di lisogangliosidi |
IT1249034B (it) * | 1990-06-29 | 1995-02-11 | Fidia Spa | Impiego del monosialoganglioside gm1 e del suo derivato estere interno per impedire l'instaurarsi della tolleranza nell'uomo all'effetto analgesico della morfina e analoghi |
IT1253832B (it) * | 1991-08-01 | 1995-08-29 | Fidia Spa | Derivati di gangliosidi |
-
1992
- 1992-03-13 IT ITMI920591A patent/IT1254280B/it active
-
1993
- 1993-03-12 ES ES96116051T patent/ES2161953T3/es not_active Expired - Lifetime
- 1993-03-12 EP EP93906509A patent/EP0630250A1/en not_active Withdrawn
- 1993-03-12 WO PCT/EP1993/000571 patent/WO1993017691A2/en not_active Application Discontinuation
- 1993-03-12 AT AT96116051T patent/ATE206053T1/de not_active IP Right Cessation
- 1993-03-12 JP JP5515350A patent/JP2872809B2/ja not_active Expired - Fee Related
- 1993-03-12 EP EP96116051A patent/EP0770389B1/en not_active Expired - Lifetime
- 1993-03-12 DE DE69330842T patent/DE69330842T2/de not_active Expired - Lifetime
-
1994
- 1994-09-12 US US08/304,391 patent/US6620792B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE69330842D1 (de) | 2001-10-31 |
JP2872809B2 (ja) | 1999-03-24 |
WO1993017691A3 (en) | 1993-11-11 |
EP0770389B1 (en) | 2001-09-26 |
ATE206053T1 (de) | 2001-10-15 |
JPH07508258A (ja) | 1995-09-14 |
EP0770389A1 (en) | 1997-05-02 |
WO1993017691A2 (en) | 1993-09-16 |
ITMI920591A1 (it) | 1993-09-13 |
ITMI920591A0 (it) | 1992-03-13 |
IT1254280B (it) | 1995-09-14 |
EP0630250A1 (en) | 1994-12-28 |
US6620792B1 (en) | 2003-09-16 |
DE69330842T2 (de) | 2002-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2052717T3 (es) | Uso de derivados de indolona para la preparacion de medicamentos para el tratamiento de la enfermedad de parkinson. | |
ES2161953T3 (es) | Utilizacion del monosialogangliosido gm1 o del n-dicloroacetil-liso-gm1 para prevenir o invertir la degeneracion neuronal inducida por un tratamiento de larga duracion con l-dopa en la terapia de la enfermedad de parkinson. | |
ES2105333T3 (es) | Combinaciones de prostaglandinas y derivados de clonidina para el tratamiento del glaucoma. | |
ES507394A0 (es) | Mejoras en el objeto de la patente de invencion n.487.721 por procedimiento de preparacion de nuevos derivados del nortropano. | |
ES2053778T3 (es) | Procedimiento para la obtencion de derivados del tiazol. | |
AU4180593A (en) | The use of complement inhibitors for the preparation of a pharmaceutical for the prophylaxis and therapy of inflammatory intestinal and skin disorders as well as purpura | |
IE780643L (en) | THERAPEUTIC APPLICATION OF d, 1-CARNITINE DERIVITIVES | |
GR3019179T3 (en) | Flupirtine in combination with antiparkinsonica against muscle bracing | |
BR8805406A (pt) | Conjunto compreendendo uma caixa fixada sobre um suporte | |
ES2164465T3 (es) | Uso de aminometil-cromanos sustituidos para evitar la degeneracion neuronal y para estimular la regeneracion neuronal. | |
ES2084579T3 (es) | Uso de buspirona en la preparacion de una composicion farmaceutica para el tratamiento del abuso del alcohol. | |
PT95117A (pt) | Metodo para o tratamento da ejaculacao precoce utilizando sertralina | |
ES2070478T3 (es) | El empleo de acetil l-carnitina en el tratamiento terapeutico de coma. | |
IT1241984B (it) | Impiego di uridina nel trattamento farmacologico delle complicazioni periferiche del diabete | |
ES2066914T3 (es) | Factores a1, a2, a3 y h del antibiotico ge 2270. | |
IT8920358A0 (it) | Impiego di derivati della fosfatidil carnitina per la preparazione di composizioni farmaceutiche aventi attivita' nella terapia delle patologie dell'uomo associate con un danno neuronale. | |
ES2078256T3 (es) | Formula farmaceutica para uso topico que contiene diclofenaco sodico. | |
BR9607996A (pt) | Derivado de aminotetralina para o tratamento de doenças cardiovasculares | |
ES2083490T3 (es) | 3,5-diyodo-l-tironina para la supresion de tsh y el tratamiento del bocio. | |
NO874241D0 (no) | Terapeutisk aktive salter. | |
UA26443A (uk) | Похідhі 20,21-диhоребурhамеhіhу, їх рацемати або оптичhі ізомери, або їх адитивhі солі з оргаhічhими кислотами, що мають hоотропhі та аhтидепресивhі властивості | |
BR0109192A (pt) | Tratamento de hipertensão ocular e glaucoma. | |
AR013538A1 (es) | Nuevos mitogenos especificos de osteoblastos, metodos para prepararlos y drogas que contienen tales compuestos | |
ES2081884T3 (es) | Factor citotoxico oligodendrocitico. | |
ES2129401T3 (es) | Uso de un compuesto terapeutico para el tratamiento de bronquitis. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 770389 Country of ref document: ES |